Genmab — Oktober 2016
-
Det er straks værre med Florian Scönharting.

-
Sagde du ikke 1200 for nyligt.

-
Jeg har ikke noget decideret kursmål. Har alene udtalt om, hvilken kurs jeg mente, at aktien vil have ved udgangen af 2016.
-
Jeg opererer heller ikke med kursmål i min analyse på Genmab hos DAF eller i mine analyser på laks.
-
Jeg tror mht biotech, så er markedet bange for at udover at Clinton bliver præsident, at demokraterne for flertal i kongressen. Dvs at Clinton derved for lettere ved at indføre en form for priskontrol på medicinske produkter
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind